GSK's Jemperli prolongs life in endometrial cancer trial. Will FDA label expansion come next?

After a quick FDA approval in a subgroup of endometrial cancer patients, GSK is trumpeting a win for its Jemperli that might help the PD-1 inhibitor expand to a broader population.

Adding Jemperli to chemotherapy significantly extended the life spans of patients with primary advanced or first recurrent endometrial cancer in the phase 3 RUBY trial, GSK said Monday.